Vistagen Therapeutics (VTGN) Non-Current Deffered Revenue (2017 - 2025)
Historic Non-Current Deffered Revenue for Vistagen Therapeutics (VTGN) over the last 9 years, with Q4 2025 value amounting to $176000.0.
- Vistagen Therapeutics' Non-Current Deffered Revenue fell 6123.35% to $176000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $176000.0, marking a year-over-year decrease of 6123.35%. This contributed to the annual value of $391000.0 for FY2025, which is 8537.77% down from last year.
- Latest data reveals that Vistagen Therapeutics reported Non-Current Deffered Revenue of $176000.0 as of Q4 2025, which was down 6123.35% from $336000.0 recorded in Q3 2025.
- Vistagen Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $2.7 million during Q1 2024, with a 5-year trough of $176000.0 in Q4 2025.
- Moreover, its 5-year median value for Non-Current Deffered Revenue was $1.7 million (2021), whereas its average is $1.5 million.
- As far as peak fluctuations go, Vistagen Therapeutics' Non-Current Deffered Revenue soared by 7547.0% in 2022, and later tumbled by 8537.77% in 2025.
- Vistagen Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $1.4 million in 2021, then surged by 75.47% to $2.5 million in 2022, then fell by 23.79% to $1.9 million in 2023, then tumbled by 76.1% to $454000.0 in 2024, then tumbled by 61.23% to $176000.0 in 2025.
- Its Non-Current Deffered Revenue was $176000.0 in Q4 2025, compared to $336000.0 in Q3 2025 and $221000.0 in Q2 2025.